AstraZeneca and the Canadian authorities are "still talking" about whether or not Exanta (ximelegatran), its blood thinner which was knocked back by the FDA, will get a licence for longer term use (atrial fibrillation/stroke prevention).
Well , no news is good news, isn't it?
No comments:
Post a Comment